178 related articles for article (PubMed ID: 26235745)
1. Stratification of resectable lung adenocarcinoma by molecular and pathological risk estimators.
Rakha E; Pajares MJ; Ilie M; Pio R; Echeveste J; Hughes E; Soomro I; Long E; Idoate MA; Wagner S; Lanchbury JS; Baldwin DR; Hofman P; Montuenga LM
Eur J Cancer; 2015 Sep; 51(14):1897-903. PubMed ID: 26235745
[TBL] [Abstract][Full Text] [Related]
2. Cell cycle progression score is a marker for five-year lung cancer-specific mortality risk in patients with resected stage I lung adenocarcinoma.
Eguchi T; Kadota K; Chaft J; Evans B; Kidd J; Tan KS; Dycoco J; Kolquist K; Davis T; Hamilton SA; Yager K; Jones JT; Travis WD; Jones DR; Hartman AR; Adusumilli PS
Oncotarget; 2016 Jun; 7(23):35241-56. PubMed ID: 27153551
[TBL] [Abstract][Full Text] [Related]
3. Validation of a molecular and pathological model for five-year mortality risk in patients with early stage lung adenocarcinoma.
Bueno R; Hughes E; Wagner S; Gutin AS; Lanchbury JS; Zheng Y; Archer MA; Gustafson C; Jones JT; Rushton K; Saam J; Kim E; Barberis M; Wistuba I; Wenstrup RJ; Wallace WA; Hartman AR; Harrison DJ
J Thorac Oncol; 2015 Jan; 10(1):67-73. PubMed ID: 25396679
[TBL] [Abstract][Full Text] [Related]
4. Prediction of distant recurrence in resected stage I and II lung adenocarcinoma.
Aramini B; Casali C; Stefani A; Bettelli S; Wagner S; Sangale Z; Hughes E; Lanchbury JS; Maiorana A; Morandi U
Lung Cancer; 2016 Nov; 101():82-87. PubMed ID: 27794412
[TBL] [Abstract][Full Text] [Related]
5. Development and Validation of an Individualized Immune Prognostic Signature in Early-Stage Nonsquamous Non-Small Cell Lung Cancer.
Li B; Cui Y; Diehn M; Li R
JAMA Oncol; 2017 Nov; 3(11):1529-1537. PubMed ID: 28687838
[TBL] [Abstract][Full Text] [Related]
6. Validation of a proliferation-based expression signature as prognostic marker in early stage lung adenocarcinoma.
Wistuba II; Behrens C; Lombardi F; Wagner S; Fujimoto J; Raso MG; Spaggiari L; Galetta D; Riley R; Hughes E; Reid J; Sangale Z; Swisher SG; Kalhor N; Moran CA; Gutin A; Lanchbury JS; Barberis M; Kim ES
Clin Cancer Res; 2013 Nov; 19(22):6261-71. PubMed ID: 24048333
[TBL] [Abstract][Full Text] [Related]
7. A novel protein-based prognostic signature improves risk stratification to guide clinical management in early-stage lung adenocarcinoma patients.
Martínez-Terroba E; Behrens C; de Miguel FJ; Agorreta J; Monsó E; Millares L; Sainz C; Mesa-Guzman M; Pérez-Gracia JL; Lozano MD; Zulueta JJ; Pio R; Wistuba II; Montuenga LM; Pajares MJ
J Pathol; 2018 Aug; 245(4):421-432. PubMed ID: 29756233
[TBL] [Abstract][Full Text] [Related]
8. Chaperone protein L-isoaspartate (D-aspartyl) O-methyltransferase as a novel predictor of poor prognosis in lung adenocarcinoma.
Saito H; Yamashita M; Ogasawara M; Yamada N; Niisato M; Tomoyasu M; Deguchi H; Tanita T; Ishida K; Sugai T; Yamauchi K
Hum Pathol; 2016 Apr; 50():1-10. PubMed ID: 26997432
[TBL] [Abstract][Full Text] [Related]
9. Early2 factor (E2F) deregulation is a prognostic and predictive biomarker in lung adenocarcinoma.
Chen L; Kurtyka CA; Welsh EA; Rivera JI; Engel BE; Muñoz-Antonia T; Yoder SJ; Eschrich SA; Creelan BC; Chiappori AA; Gray JE; Ramirez JL; Rosell R; Schabath MB; Haura EB; Chen DT; Cress WD
Oncotarget; 2016 Dec; 7(50):82254-82265. PubMed ID: 27756884
[TBL] [Abstract][Full Text] [Related]
10. Gender Differences in Long-Term Survival after Surgery for Non-Small Cell Lung Cancer.
Yoshida Y; Murayama T; Sato Y; Suzuki Y; Saito H; Nomura Y
Thorac Cardiovasc Surg; 2016 Sep; 64(6):507-14. PubMed ID: 26366891
[TBL] [Abstract][Full Text] [Related]
11. Oncologic outcomes of segmentectomy compared with lobectomy for clinical stage IA lung adenocarcinoma: propensity score-matched analysis in a multicenter study.
Tsutani Y; Miyata Y; Nakayama H; Okumura S; Adachi S; Yoshimura M; Okada M
J Thorac Cardiovasc Surg; 2013 Aug; 146(2):358-64. PubMed ID: 23477694
[TBL] [Abstract][Full Text] [Related]
12. An Aggressive Subtype of Stage I Lung Adenocarcinoma with Molecular and Prognostic Characteristics Typical of Advanced Lung Cancers.
Dama E; Melocchi V; Dezi F; Pirroni S; Carletti RM; Brambilla D; Bertalot G; Casiraghi M; Maisonneuve P; Barberis M; Viale G; Vecchi M; Spaggiari L; Bianchi F; Di Fiore PP
Clin Cancer Res; 2017 Jan; 23(1):62-72. PubMed ID: 27358486
[TBL] [Abstract][Full Text] [Related]
13. Unique microRNAs in lung adenocarcinoma groups according to major TKI sensitive EGFR mutation status.
Pak MG; Lee CH; Lee WJ; Shin DH; Roh MS
Diagn Pathol; 2015 Jul; 10():99. PubMed ID: 26170125
[TBL] [Abstract][Full Text] [Related]
14. Positive intraoperative pleural lavage cytology is a predictive marker of disease recurrence in stage I lung adenocarcinoma.
Yanagawa N; Shiono S; Abiko M; Abe M; Watanabe K; Watanabe I; Uematsu M; Ogata SY; Sato T; Tamura G
Interact Cardiovasc Thorac Surg; 2014 May; 18(5):621-5. PubMed ID: 24532312
[TBL] [Abstract][Full Text] [Related]
15. The prognostic role of pathologic invasive component size, excluding lepidic growth, in stage I lung adenocarcinoma.
Tsutani Y; Miyata Y; Mimae T; Kushitani K; Takeshima Y; Yoshimura M; Okada M
J Thorac Cardiovasc Surg; 2013 Sep; 146(3):580-5. PubMed ID: 23778085
[TBL] [Abstract][Full Text] [Related]
16. Analytical validation of a proliferation-based molecular signature used as a prognostic marker in early stage lung adenocarcinoma.
Warf MB; Fosso PG; Hughes E; Perry M; Brown KL; Reid JE; Kolquist KA; Wagner S; Gutin A; Roa B
Biomark Med; 2015; 9(9):901-10. PubMed ID: 26158298
[TBL] [Abstract][Full Text] [Related]
17. KRAS Mutation Is a Significant Prognostic Factor in Early-stage Lung Adenocarcinoma.
Kadota K; Sima CS; Arcila ME; Hedvat C; Kris MG; Jones DR; Adusumilli PS; Travis WD
Am J Surg Pathol; 2016 Dec; 40(12):1579-1590. PubMed ID: 27740967
[TBL] [Abstract][Full Text] [Related]
18. The prognostic impact of KRAS, its codon and amino acid specific mutations, on survival in resected stage I lung adenocarcinoma.
Izar B; Zhou H; Heist RS; Azzoli CG; Muzikansky A; Scribner EE; Bernardo LA; Dias-Santagata D; Iafrate AJ; Lanuti M
J Thorac Oncol; 2014 Sep; 9(9):1363-9. PubMed ID: 25122432
[TBL] [Abstract][Full Text] [Related]
19. Development of a novel prognostic signature of long non-coding RNAs in lung adenocarcinoma.
Zheng S; Zheng D; Dong C; Jiang J; Xie J; Sun Y; Chen H
J Cancer Res Clin Oncol; 2017 Sep; 143(9):1649-1657. PubMed ID: 28409273
[TBL] [Abstract][Full Text] [Related]
20. The novel histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification system of lung adenocarcinoma is a stage-independent predictor of survival.
Warth A; Muley T; Meister M; Stenzinger A; Thomas M; Schirmacher P; Schnabel PA; Budczies J; Hoffmann H; Weichert W
J Clin Oncol; 2012 May; 30(13):1438-46. PubMed ID: 22393100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]